We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer.
- Authors
TAKAAKI ARIGAMI; DAISUKE MATSUSHITA; KEISHI OKUBO; TAKAKO TANAKA; KEN SASAKI; YUSUKE TSURUDA; YOSHIAKI KITA; SHINICHIRO MORI; HIROSHI KURAHARA; YOSHIKAZU UENOSONO; TAKAO OHTSUKA
- Abstract
Background/Aim: To investigate changes in postprogression chemotherapy (PPC) before and after nivolumab approval and determine their prognostic impact. Patients and Methods: A total of 146 patients with unresectable gastric cancer who had at least progressive disease after first- and/or second-line chemotherapy were retrospectively enrolled. Results: Among the 146 patients, 46 and 23 received ramucirumab and nivolumab, respectively. Moreover, 95 and 62 patients received PPC after first- and second-line chemotherapy, respectively. Group B (i.e., at least chemotherapy after nivolumab approval) had significantly higher proportions of patients receiving ramucirumab therapy, nivolumab therapy, and PPC after first- or secondline chemotherapy compared to group A (i.e., termination of chemotherapy before nivolumab approval). Group A had significantly poorer prognosis than group B. Multivariate analysis showed that age, number of distant metastatic sites, and ramucirumab therapy were independent prognostic factors. Conclusion: Changes in chemotherapeutic strategies, including PPC, might contribute to improved prognosis in patients with advanced gastric cancer
- Subjects
CANCER chemotherapy; STOMACH cancer; NIVOLUMAB; PROGNOSIS; DRUGS
- Publication
In Vivo, 2022, Vol 36, Issue 1, p409
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12718